Trials that use: Multiple imputation / missing data
New to this method? Read the tutorial →
20,324 results
- EVERESTIndependent statistical analysis of EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EVERESTIIRCTIndependent statistical analysis of Pivotal Study of a Percutaneous Mitral Valve Repair System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00209274).
- EvergazeIndependent statistical analysis of Visual Enhancement Device in Low Vision Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03794752).
- EVERGREENIndependent statistical analysis of A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease…
- everlinQ endoAVF Post Market Study: Complete Statistical AnalysisIndependent statistical analysis of everlinQ endoAVF Post Market Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02682420).
- Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas: Complete Statistical AnalysisIndependent statistical analysis of Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity: Complete Statistical AnalysisIndependent statistical analysis of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium: Complete Statistical AnalysisIndependent statistical analysis of Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00805129).
- Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex: Complete Statistical AnalysisIndependent statistical analysis of Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Everolimus for Cancer With TSC1 or TSC2 Mutation: Complete Statistical AnalysisIndependent statistical analysis of Everolimus for Cancer With TSC1 or TSC2 Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02201212).
- Everolimus for Children With Recurrent or Progressive Ependymoma: Complete Statistical AnalysisIndependent statistical analysis of Everolimus for Children With Recurrent or Progressive Ependymoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02155920).
- Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations: Complete Statistical AnalysisIndependent statistical analysis of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Everolimus Monotherapy as Immunosuppression After Liver Transplant: Complete Statistical AnalysisIndependent statistical analysis of Everolimus Monotherapy as Immunosuppression After Liver Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04063865).
- Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.: Complete Statistical AnalysisIndependent statistical analysis of Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Everolimus Versus Placebo in Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Everolimus Versus Placebo in Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01111058).
- Everolimus With and Without Temozolomide in Adult Low Grade Glioma: Complete Statistical AnalysisIndependent statistical analysis of Everolimus With and Without Temozolomide in Adult Low Grade Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02023905).
- Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy: Complete Statistical AnalysisIndependent statistical analysis of Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- EVERZOTAIndependent statistical analysis of Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EVIDENCEIndependent statistical analysis of Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment: primary endpoint results, effect estimate with confidence interval,…
- EvidenceIndependent statistical analysis of Spinal Cord Stimulation With Precision® System Versus Reoperation for Failed Back Surgery Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EVIDENCEIndependent statistical analysis of A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Evidence-based Intervention for Improved Head Impact Safety in Youth Football – Aim 1 and Aim 3: Complete Statistical AnalysisIndependent statistical analysis of Evidence-based Intervention for Improved Head Impact Safety in Youth Football - Aim 1 and Aim 3: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- EVINCIIndependent statistical analysis of Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00979199).
- EVIPIndependent statistical analysis of Etanercept and Vascular Function in Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01989689).
- EVITAIndependent statistical analysis of 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance…
- EVITAIndependent statistical analysis of Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EvKIndependent statistical analysis of Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- EVOGUARDIndependent statistical analysis of Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EVOKEIndependent statistical analysis of Safety and Efficacy Study of the Evoke™ SCS System With Feedback vs. Conventional Stimulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EVOKE-01Independent statistical analysis of Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- EVOLUTIONIndependent statistical analysis of Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).: primary endpoint results, effect estimate with confidence interval, sample-size…
- EVOLVEIndependent statistical analysis of Epanova® for Lowering Very High Triglycerides: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01242527).
- EVOLVEIndependent statistical analysis of E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- EVOLVE-1Independent statistical analysis of Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.: primary endpoint results, effect…
- EVOLVE48Independent statistical analysis of A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- EVOLVEIIIndependent statistical analysis of Epanova® for Lowering Very High Triglycerides II (EVOLVE II): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02009865).
- EVTGCIndependent statistical analysis of Evaluation of Videoconferencing Versus Telephone Genetic Counseling: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02108977).
- EW-DIndependent statistical analysis of A Community Wellness Program for Adults Living With Long-term Physical Disability: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia: Complete Statistical AnalysisIndependent statistical analysis of EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies: primary endpoint results, effect estimate with…
- Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EX-ODCKDIndependent statistical analysis of Exercise in Obese Diabetic Patients With Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01036490).
- ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors: Complete Statistical AnalysisIndependent statistical analysis of ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ExAblate Treatment of Uterine Fibroids for Fertility Enhancement: Complete Statistical AnalysisIndependent statistical analysis of ExAblate Treatment of Uterine Fibroids for Fertility Enhancement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00730886).
- EXACTIndependent statistical analysis of The Exercise And Colorectal Cancer Treatment Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03975491).
- EXALTIndependent statistical analysis of Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers: Complete Statistical AnalysisIndependent statistical analysis of Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Examination of the Effects of Chromium Levels on Glucose Metabolism, Lipid Metabolism, Morbidity and Mortality Rates in Patients Followed in Intensive Care Unit: Complete Statistical AnalysisIndependent statistical analysis of Examination of the Effects of Chromium Levels on Glucose Metabolism, Lipid Metabolism, Morbidity and Mortality Rates in Patients Followed in Intensive Care Unit: primary endpoint results, effect estimate…